Vol. 2 No. 11 (2022)
Reimbursement Reviews

Mogamulizumab (Poteligeo)

Published November 3, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Mogamulizumab (Poteligeo), 20 mg/5 mL single-use vial IV infusion, 4 mg/mL.
  • Indication: For the treatment of adult patients with relapsed or refractory MF or SS after at least 1 prior systemic therapy.